This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mukwaya, G.
Right arrow Articles by McCallister, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mukwaya, G.
Right arrow Articles by McCallister, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2005, p. 4903-4910, Vol. 49, No. 12
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.12.4903-4910.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Interaction of Ritonavir-Boosted Tipranavir with Loperamide Does Not Result in Loperamide-Associated Neurologic Side Effects in Healthy Volunteers

Geoffrey Mukwaya,1* Thomas MacGregor,1 David Hoelscher,2 Thomas Heming,3,{dagger} Daniel Legg,1 Kelli Kavanaugh,1 Phillip Johnson,1 John P. Sabo,1 and Scott McCallister1,{ddagger}

Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut,1 PPD Development, Austin, Texas,2 University of Texas, Houston, Texas3

Received 27 April 2005/ Returned for modification 15 June 2005/ Accepted 16 August 2005

Loperamide (LOP) is a peripherally acting opioid receptor agonist used for the management of chronic diarrhea through the reduction of gut motility. The lack of central opioid effects is partly due to the efflux activity of the multidrug resistance transporter P-glycoprotein (P-gp) at the blood-brain barrier. The protease inhibitors are substrates for P-gp and have the potential to cause increased LOP levels in the brain. Because protease inhibitors, including tipranavir (TPV), are often associated with diarrhea, they are commonly used in combination with LOP. The level of respiratory depression, the level of pupil constriction, the pharmacokinetics, and the safety of LOP alone compared with those of LOP-ritonavir (RTV), LOP-TPV, and LOP-TPV-RTV were evaluated in a randomized, open-label, parallel-group study with 24 healthy human immunodeficiency virus type 1-negative adults. Respiratory depression was assessed by determination of the ventilatory response to carbon dioxide. Tipranavir-containing regimens (LOP-TPV and LOP-TPV-RTV) caused decreases in the area under the concentration-time curve from time zero to infinity for LOP (51% and 63% decreases, respectively) and its metabolite (72% and 77% decreases, respectively), whereas RTV caused increases in the levels of exposure of LOP (121% increase) and its metabolite (44% increase). In vitro and in vivo data suggest that TPV is a substrate for and an inducer of P-gp activity. The respiratory response to LOP in combination with TPV and/or RTV was not different from that to LOP alone. There was no evidence that LOP had opioid effects in the central nervous system, as measured indirectly by CO2 response curves and pupillary response in the presence of TPV and/or RTV.

* Corresponding author. Mailing address: Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877. Phone: (203) 791-6036. Fax: (203) 798-5433. E-mail: gmukwaya{at}rdg.boehringer-ingelheim.com.

{dagger} Present address: Oman Medical College, P.O. Box 391, Postal Code 321, Al Tareef, Sohar, Sultanate of Oman.

{ddagger} Present address: Global Medical Affairs, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08540.

Antimicrobial Agents and Chemotherapy, December 2005, p. 4903-4910, Vol. 49, No. 12
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.12.4903-4910.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Chen, L., Sabo, J. P., Philip, E., Mao, Y., Norris, S. H., MacGregor, T. R., Wruck, J. M., Garfinkel, S., Castles, M., Brinkman, A., Valdez, H. (2007). Steady-State Disposition of the Nonpeptidic Protease Inhibitor Tipranavir when Coadministered with Ritonavir. Antimicrob. Agents Chemother. 51: 2436-2444 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»